What is epclusa?

What is Epclusa?

Epclusa is a prescription antiviral medication used to treat chronic hepatitis C in adults and children 3 years and older. It combines two antiviral drugs—sofosbuvir and velpatasvir—to target multiple genotypes of the hepatitis C virus.

What does Epclusa treat?

It clears the virus from the blood in most patients, helping prevent liver damage, cirrhosis, and liver failure. Treatment usually lasts 12 weeks for simple cases.

How does Epclusa work?

Sofosbuvir blocks an enzyme the virus needs to multiply, while velpatasvir stops the virus from assembling new particles. Both drugs work together to stop the virus from reproducing.

Why is Epclusa preferred over older treatments?

Epclusa works across all six major genotypes of hepatitis C, often without needing interferon shots that caused heavy side effects. It has a high cure rate, reported over 95 percent in clinical trials.

Can biosimilars or generics enter the market?

Generic versions of Epclusa are already available in the United States and some international markets. Generics typically offer the original drug at lower prices, helping patients who lack insurance coverage.

What is the patent timeline?

The compound patent covering sofosbuvir and velpatasvir expires around 2030 in the U.S. [1]. Some method-of-use and formulation patents may extend protection further.